Related references
Note: Only part of the references are listed.
Article
Cell Biology
Hua Luo et al.
Summary: A previous study found that circ-OXCT1 is highly expressed in lung adenocarcinoma tumor tissues, but its role and mechanism in non-small cell lung cancer (NSCLC) progression remains unclear. This study demonstrated that circ-OXCT1 promotes NSCLC progression by regulating SLC1A5 expression through miR-516b-5p. These findings suggest a potential circRNA-targeted therapy for NSCLC.
Article
Cell Biology
Yuxi Liu et al.
Summary: This study investigates the role of m6A-modified circRERE in osteoarthritis (OA) and its mechanism. The results show that circRERE can target miR-195-5p/IRF2BPL/beta-catenin to exert chondroprotective effects. The study suggests that targeting m6A-modified circRERE and its target miR-195-5p/IRF2BPL/beta-catenin may be potential therapeutic strategies for OA treatment.
CELL PROLIFERATION
(2023)
Article
Biochemistry & Molecular Biology
Min Chen et al.
Summary: Studies have found that hsa_circ_0063526 is an oncogenic circular RNA in non-small cell lung cancer (NSCLC), but its molecular mechanism is not completely understood. It was discovered that circRANGAP1 functions as a sponge of miR-653-5p to increase COL11A1 expression, promoting NSCLC development and metastasis.
BIOCHEMICAL GENETICS
(2023)
Review
Pharmacology & Pharmacy
Qiuyun Xue et al.
Summary: Osteoarthritis (OA) is an age-related joint disease characterized by chronic inflammation, progressive articular cartilage destruction, and subchondral bone sclerosis. CircRNAs are a class of non-coding RNA with a circular structure that play a crucial role in the pathophysiology of OA, particularly through ceRNA mechanisms. CircRNAs have the potential to serve as biomarkers for diagnosing and prognosing OA. Differential expression of circRNAs has been observed in OA patients, suggesting their involvement in the pathogenesis of the disease. Experimental studies have demonstrated that intra-articular injection of modified circRNAs can effectively alleviate OA. Exosomal circRNAs and methylated circRNAs provide new insights for the treatment of OA. Understanding the important roles of circRNAs in OA will enhance our knowledge of the disease's pathogenesis and may lead to the development of new biomarkers and drug targets for diagnosis and treatment.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Shu Song et al.
Summary: Studying the mechanism of cisplatin resistance in NSCLC may help identify new specific targets. The study found that circANKRD28 was significantly decreased in NSCLC, and its overexpression inhibited cisplatin resistance by regulating the miR-221-3p/SOCS3 axis.
JOURNAL OF GENE MEDICINE
(2023)
Article
Respiratory System
Mingming Jin et al.
Summary: This study found that the expression of hsa_circ_0046701 (circ-YES1) increased in non-small cell lung cancer cells, while its inhibition slowed down cell proliferation and migration. Further research revealed that circ-YES1 promotes tumor development through the miR-142-3p-HMGB1 axis. These findings suggest that circ-YES1 may be a new therapeutic target for non-small cell lung cancer.
RESPIRATORY RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Qiong Yuan et al.
Summary: We found that DICAR, a conserved circRNA, was downregulated in diabetic mouse hearts. DICAR had an inhibitory effect on diabetic cardiomyopathy (DCM), and its deficiency led to cardiac dysfunction, hypertrophy, and fibrosis in mice. On the molecular level, DICAR-VCP-Med12 degradation could be the underlying mechanism for DICAR-mediated effects. The synthesized DICAR-JP showed similar effects, and the expression of DICAR in diabetic patients was lower than in healthy controls, suggesting that DICAR and DICAR-JP could be potential drug candidates for DCM.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Article
Oncology
Afeez Adekunle Ishola et al.
Summary: Lung cancers, particularly non-small cell lung cancers, have a poor prognosis. A circular noncoding RNA called C190 has been identified as a negative prognostic biomarker for lung cancer, and this study explores its mechanistic function and potential as a therapeutic target for NSCLC.
Article
Oncology
Suo Liu et al.
Summary: The study revealed that hsa_circ_0005576 regulates the proliferation and apoptosis of LUAD cells through the miR-512-5p/IGF1R signaling pathway, contributing to the resistance to osimertinib. This research provides new insights into the mechanisms underlying osimertinib resistance in LUAD.
Article
Biochemistry & Molecular Biology
Ling-Xian Zhang et al.
Summary: HMGB2-derived circular RNA (circHMGB2) plays a role in promoting tumor progression in LUAD and LUSC, mainly by reshaping the tumor microenvironment and regulating anti-PD-1 resistance. In addition, the expression level of circHMGB2 is also found to be associated with patient prognosis.
Review
Oncology
Xavier Cansouline et al.
Summary: This article reviews the latest data on the adjuvant and neoadjuvant use of tyrosine kinase inhibitors, with a focus on their benefits, potential challenges, and the impact of mutation variability and financial evaluations. The review finds that tyrosine kinase inhibitors often show disease-free survival benefits, but overall survival improvement remains difficult, potentially due to variability in stages and mutations. Additionally, the safety profiles of the inhibitors are acceptable, but high costs and limited accessibility pose challenges. Overall, tyrosine kinase inhibitors offer promising opportunities for tailored treatment designs.
Article
Oncology
Xia-Hui Lin et al.
Summary: This study revealed that circRanGAP1 is upregulated in HCC cells and clinical tissues, and its increased levels are associated with enlarged tumors and advanced TNM stage. CircRanGAP1 promotes HCC progression through the miR-27b-3p/NRAS/ERK axis and regulates tumor-associated macrophage infiltration levels by sponging miR-27b-3p. The circRANGAP1/NRAS axis may be an important potential treatment target against HCC.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
Article
Oncology
Youtang Li et al.
Summary: This study revealed that circ_0010235 and FAM83F were upregulated in PTX-resistant NSCLC. Inhibition of circ_0010235 reduced resistance, proliferation, angiogenesis, migration/invasion, and promoted apoptosis in cells. MiR-512-5p interacted with circ_0010235 and FAM83F. Silencing circ_0010235 improved tumor sensitivity to PTX.
Article
Biotechnology & Applied Microbiology
Qingjun Meng et al.
Summary: Circ_0070659 is significantly upregulated in non-small cell lung cancer (NSCLC) and promotes tumor cell proliferation and invasion through competitive binding with miR-377 and activation of RAB3C. This study reveals a novel signaling pathway and provides a new target for the treatment of NSCLC.
Article
Chemistry, Multidisciplinary
Chun-shuang Ma et al.
Summary: The study demonstrates the crucial role of NRF2 in mediating resistance to EGFR-TKIs by regulating the expression of GPX4 and SOD2. Targeting the NRF2-GPX4/SOD2 pathway may be a potential strategy for overcoming resistance to EGFR-TKIs, providing a novel approach in treating NSCLC.
ACTA PHARMACOLOGICA SINICA
(2021)
Article
Oncology
Rebecca L. Siegel et al.
Summary: Every year, the American Cancer Society projects the numbers of new cancer cases and deaths in the United States, with the latest data showing a significant decline in lung cancer mortality, while prostate cancer mortality has plateaued and breast and colorectal cancer mortality have slowed. Improvements in treatment have accelerated progress against lung cancer, leading to a record drop in overall cancer mortality.
CA-A CANCER JOURNAL FOR CLINICIANS
(2021)
Article
Multidisciplinary Sciences
Botai Li et al.
Summary: It was found that circNDUFB2 is downregulated in NSCLC tissues and inhibits the growth and metastasis of NSCLC cells by enhancing the interaction between TRIM25 and IGF2BPs. circNDUFB2 also activates anti-tumor immune responses by binding to RIG-I.
NATURE COMMUNICATIONS
(2021)
Article
Biochemistry & Molecular Biology
Shi-Wei Chen et al.
Summary: In human non-small cell lung cancer (NSCLC) tissues, high expression levels of circUSP7 are associated with poor clinical prognosis and dysfunction of CD8(+) T cells. CircUSP7 found in NSCLC patient plasma is mainly secreted by NSCLC cells via exosomes, inhibiting CD8(+) T cell function by upregulating SHP2 expression. Additionally, circUSP7 may contribute to resistance to anti-PD1 immunotherapy in NSCLC patients.
Article
Chemistry, Medicinal
Katarzyna Beata Skorska et al.
Summary: This study found a positive correlation between serum SOD1 and SOD2 concentrations and all-cause mortality in lung cancer patients. Clinical stage III and IV disease was the strongest predictor. SOD1 showed better predictive ability for overall survival in patients.
Article
Oncology
Zhexin Wang et al.
Article
Oncology
Jun Lu et al.
Article
Cell Biology
Lili Cao et al.
CELL DEATH & DISEASE
(2020)
Article
Cell Biology
Guanqun Huang et al.
CELL DEATH & DISEASE
(2020)
Article
Oncology
Bin Cao et al.
MOLECULAR MEDICINE REPORTS
(2019)
Article
Cell Biology
Jinglei Liu et al.
Article
Oncology
Kaili Chu et al.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2016)
Review
Biochemistry & Molecular Biology
Philippe Becuwe et al.
FREE RADICAL BIOLOGY AND MEDICINE
(2014)
